0H79 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and large equity provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing risk, supports continued R&D investment or selective partnering, and gives management optionality to execute development programs without immediate liquidity pressure.
Positive Clinical Proof-of-conceptRobust Phase 2a data in plaque psoriasis materially de-risks the lead dermatology program and strengthens the clinical narrative. Durable proof-of-concept supports regulatory strategy, enhances partnering and licensing leverage, and increases the asset's long-term commercial potential in dermatology.
Governance And Shareholder AlignmentClear shareholder support for board composition, auditor ratification, and executive compensation indicates governance stability. Stable governance reduces execution risk, facilitates strategic decision-making and capital actions, and improves prospects for consistent long-term program delivery.
Bears Say
Heavy And Rising Cash BurnSubstantial and increasing operating cash outflows create a persistent funding requirement that will force capital raises or partnerships. Even with a strong balance sheet, sustained high burn narrows strategic flexibility, raises dilution risk, and constrains the pace of parallel development programs over months to years.
Pre-revenue With Widening LossesLack of revenue and growing net losses mean the company remains dependent on external financing and partnership outcomes. This structural absence of operating cash generation delays self-sustaining profitability, increases execution risk for commercialization, and pressures returns for equity holders over the medium term.
License Dosing Restrictions Constrain ExpansionNew dosing and indication limits in the IL-23 license narrow Oruka's ability to pursue inflammatory bowel disease indications in the near term. These contractual constraints can slow entry into attractive markets, complicate partnering or M&A timing, and cap near-term value capture from the IL-23 franchise.
Oruka Therapeutics News
0H79 FAQ
What was Oruka Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Oruka Therapeutics’s market cap?
Oruka Therapeutics’s market cap is $5.82B.
When is Oruka Therapeutics’s upcoming earnings report date?
Oruka Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 9 days.
How were Oruka Therapeutics’s earnings last quarter?
Oruka Therapeutics released its earnings results on May 13, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.547 by $0.067.
Is Oruka Therapeutics overvalued?
According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued.
Does Oruka Therapeutics pay dividends?
Oruka Therapeutics does not currently pay dividends.
What is Oruka Therapeutics’s EPS estimate?
Oruka Therapeutics’s EPS estimate is -0.51.
How many shares outstanding does Oruka Therapeutics have?
Oruka Therapeutics has 60,312,100 shares outstanding.
What happened to Oruka Therapeutics’s price movement after its last earnings report?
Oruka Therapeutics reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.547. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Oruka Therapeutics?
Currently, no hedge funds are holding shares in GB:0H79
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oruka Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$147.63 (― Upside)
$147.63 (― Upside)
Blogger Sentiment
Bullish
GB:0H79 Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth $300.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
532.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
33.77%
Trailing 12-Months
Company Description
Oruka Therapeutics
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
0H79 Stock 12 Month Forecast
Average Price Target
―Verastem
―
AnaptysBio
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―